Discover how US drugmaker Alnylam is transforming from a rare disease specialist into a major therapeutic platform company and why the Edinburgh Worldwide team remain confident in the significant long-term potential. Capital at risk.
Edinburgh Worldwide: stock spotlight on Alnylam
More Articles
-
AI Isn’t Coming For Your Job. It’s Coming For Your Mind
Baillie Gifford
10 March 2026
-
Retirement income: smooth the journey, not the market
Baillie Gifford
09 March 2026
-
Edinburgh Worldwide: Manager Insights
Baillie Gifford
05 March 2026
-
SAINTS spotlight: patience bears fruit
Baillie Gifford
03 March 2026
-
Baillie Gifford UK Growth Trust webinar
Baillie Gifford
27 February 2026
Editor's Picks
Loading...